Replimune Group, Inc. (REPL) News
Filter REPL News Items
REPL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
REPL News Highlights
- For REPL, its 30 day story count is now at 3.
- Over the past 23 days, the trend for REPL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about REPL are DEC and ST.
Latest REPL News From Around the Web
Below are the latest news stories about REPLIMUNE GROUP INC that investors may wish to consider to help them evaluate REPL as an investment opportunity.
Replimune to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceWOBURN, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 11:15 AM PT at the Westin St. Francis Hotel in San Francisco, CA. A simultaneous webcast will be available in the Investors |
An Intrinsic Calculation For Replimune Group, Inc. (NASDAQ:REPL) Suggests It's 24% UndervaluedKey Insights Using the 2 Stage Free Cash Flow to Equity, Replimune Group fair value estimate is US$9.64 Replimune Group... |
Why Is Replimune (REPL) Stock Down 48% Today?Replimune stock is dropping on Tuesday as investors in REPL shares react to a clinical trial missing both of its primary endpoints. |
Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin CancersRP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to cemiplimab in the CERPASS clinical trial, but did not meet either of the two primary endpoints Positive data update for full 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma reinforces durable benefit; biologics license application (BLA) submission planned for 2H 2024 RP1 monotherapy data from ARTACUS clinical trial a |
Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma ResearchRP2 as monotherapy and in combination with nivolumab showed a favorable safety profile and durable responses in nearly 30 percent of patients, all with previously treated diseaseWOBURN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced updated data from a cohort of metastatic uveal melanoma patients enrolled in the open-label, multicent |
Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate UpdateThe Company plans to hold a conference call in early December to provide a comprehensive RP1 skin cancer program update including: Topline data from the CERPASS clinical trial of RP1 combined with Libtayo in cutaneous squamous cell carcinomaAn initial data snapshot for all 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanomaInitial data from the IGNYTE cohort of RP1 in anti-PD1 failed non-melanoma skin cancersA recap of interim data from the ARTACUS clinical trial |
Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patientsWOBURN, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced updated interim results from ARTACUS, a Phase 1/2 clinical trial evaluating RP1 monotherapy for the treatment of skin cancers in patients who have had solid |
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WOBURN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the grant of inducement equity awards to Emily Hill, the Company’s newly appointed Chief Financial Officer. The inducement awards consist of a non-qualified stock option to purchase 125,000 shares of the Company's common stock and restricted stock units representing 83,330 share |
Replimune Announces Appointment of Emily Hill as Chief Financial OfficerWOBURN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the appointment of Emily Hill as Chief Financial Officer. Ms. Hill was most recently CFO of the commercial stage biotech company PTC Therapeutics and has more than 15 years of experience in the biotechnology and life sciences industry having held senior financial management and |
Insider Sell: Pamela Esposito Sells 5,658 Shares of Replimune Group IncOn September 12, 2023, Pamela Esposito, the Chief Business Officer of Replimune Group Inc (NASDAQ:REPL), sold 5,658 shares of the company. |